Tags

Type your tag names separated by a space and hit enter

Tiagabine in anxiety disorders.
Expert Opin Pharmacother. 2006 Oct; 7(14):1977-87.EO

Abstract

GABA has been implicated in both the aetiology and treatment of anxiety. Tiagabine is currently the only selective GABA reuptake inhibitor available in US markets; it exerts its action via GAT-1 transporter blockade presynaptically, facilitating GABA neurotransmission. Preclinical studies and current human studies suggest tiagabine possesses anxiolytic properties. The anxiolytic properties of tiagabine have also been suggested in a number of case series, open-label studies and placebo-controlled studies in patients with different anxiety disorders. Throughout these studies, tiagabine has been reasonably tolerated; the most commonly reported adverse events include dizziness, headache and nausea. Tiagabine may be a useful addition to currently available drugs for anxiety; however, the data from small open-label investigations remain to be confirmed in larger controlled studies.

Authors+Show Affiliations

Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA. schwartzresearch1@yahoo.comNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17020423

Citation

Schwartz, Thomas L., and Nikhil Nihalani. "Tiagabine in Anxiety Disorders." Expert Opinion On Pharmacotherapy, vol. 7, no. 14, 2006, pp. 1977-87.
Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin Pharmacother. 2006;7(14):1977-87.
Schwartz, T. L., & Nihalani, N. (2006). Tiagabine in anxiety disorders. Expert Opinion On Pharmacotherapy, 7(14), 1977-87.
Schwartz TL, Nihalani N. Tiagabine in Anxiety Disorders. Expert Opin Pharmacother. 2006;7(14):1977-87. PubMed PMID: 17020423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tiagabine in anxiety disorders. AU - Schwartz,Thomas L, AU - Nihalani,Nikhil, PY - 2006/10/6/pubmed PY - 2006/10/13/medline PY - 2006/10/6/entrez SP - 1977 EP - 87 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 7 IS - 14 N2 - GABA has been implicated in both the aetiology and treatment of anxiety. Tiagabine is currently the only selective GABA reuptake inhibitor available in US markets; it exerts its action via GAT-1 transporter blockade presynaptically, facilitating GABA neurotransmission. Preclinical studies and current human studies suggest tiagabine possesses anxiolytic properties. The anxiolytic properties of tiagabine have also been suggested in a number of case series, open-label studies and placebo-controlled studies in patients with different anxiety disorders. Throughout these studies, tiagabine has been reasonably tolerated; the most commonly reported adverse events include dizziness, headache and nausea. Tiagabine may be a useful addition to currently available drugs for anxiety; however, the data from small open-label investigations remain to be confirmed in larger controlled studies. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/17020423/Tiagabine_in_anxiety_disorders_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.7.14.1977 DB - PRIME DP - Unbound Medicine ER -